Chemours Co

Listed Company

CCCIK 0001627223NYSELarge AcceleratedChemicals & Allied ProductsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$5.81B

Net Income

$-386.00M

Total Assets

$7.38B

Equity

$250.00M

Shares Out

150.09M

Op. Cash Flow

$264.00M

Business

Chemours Co is a leading global provider of performance chemicals used as key inputs in products and processes across diverse industries. It offers industrial and specialty chemical products including refrigerants (Opteon™, Freon™), titanium dioxide (Ti-Pure™) pigment, high-end fluoropolymers and advanced materials (Teflon™, Viton™, Krytox™, Nafion™), propellants, blowing agents, specialty solvents, membranes, resins, coatings, and related technical services. The company manages operations through three reportable segments—Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials—focused on refrigerants/thermal solutions, TiO2 pigment, and advanced polymers/materials. Chemours operates production and distribution facilities worldwide, sells via direct and reseller channels, maintains logistics fleets, and serves customers in roughly 110 countries across refrigeration, coatings, plastics, transportation, electronics, industrial, and energy markets.

Summary from filing dated 2025-02-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	5,808	5,782	6,078	6,831	6,345
Cost of goods sold	4,906	4,640	4,776	5,215	4,964
Gross profit	902	1,142	1,302	1,616	1,381
Selling, general, and administrative expense	799	598	1,286	710	592
Research and development expense	108	109	108	118	107
Restructuring, asset-related, and other charges	59	60	153	16	6
Goodwill impairment charge	0	56	—	—	—
Total other operating expenses	966	823	1,547	844	705
Equity in earnings of affiliates	35	43	45	55	43
Interest expense, net	−269	−263	−208	−163	−185
Loss on extinguishment of debt	−5	−1	−1	7	−21
Other income, net	26	8	91	70	163
(Loss) Income before income taxes	−277	106	−318	741	676
(Benefit from) provision for income taxes	109	37	−66	163	68
Net (loss) income	−386	69	−252	578	608
Less: Net income attributable to non-controlling interests	—	—	1	—	—
Net (loss) income attributable to Chemours	−386	69	−253	578	608
Basic (loss) earnings per share of common stock	−2.57	0.46	−1.7	3.72	3.69
Diluted (loss) earnings per share of common stock	−2.57	0.46	−1.7	3.65	3.6

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-09-30	FY 2025 2025-06-30	FY 2025 2025-03-31	FY 2024 2024-12-31
Cash and cash equivalents	670	—	—	—	713
Restricted cash and restricted cash equivalents	2	—	—	—	0
Accounts and notes receivable, net	679	—	—	—	770
Inventories	1,569	—	—	—	1,463
Prepaid expenses and other	80	—	—	—	71
Assets held for sale	1	—	—	—	—
Total current assets	3,001	—	—	—	3,017
Property, plant, and equipment	9,920	9,839	9,787	9,629	9,577
Less: Accumulated depreciation	−6,842	—	—	—	−6,389
Property, plant, and equipment, net	3,078	3,096	3,127	3,136	3,188
Operating lease right-of-use assets	271	273	275	281	265
Goodwill	46	—	—	—	46
Other intangible assets, net	2	—	—	—	3
Investments in affiliates	160	—	—	—	152
Assets held for sale, non-current	21	—	—	—	—
Restricted cash and restricted cash equivalents	52	—	—	—	50
Other assets	751	690	684	764	788
Total assets	7,382	7,546	7,462	7,376	7,509
Accounts payable	954	—	—	—	1,156
Compensation and other employee-related cost	96	—	—	—	99
Short-term and current maturities of long-term debt	42	—	—	—	54
Current environmental remediation	88	—	—	—	115
Other accrued liabilities	506	580	585	396	396
Total current liabilities	1,686	1,871	1,827	1,668	1,820
Long-term debt, net	4,099	4,104	4,108	4,069	4,059
Operating lease liabilities	191	197	201	208	198
Long-term environmental remediation	530	—	—	—	456
Deferred income taxes	37	27	28	—	35
Other liabilities	588	—	—	—	369
Total liabilities	7,131	—	7,232	6,809	6,937
Commitments and contingent liabilities	—	—	—	—	—
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024)	2	—	—	—	2
Treasury stock, at cost (48,826,793 shares at December 31, 2025; 48,871,602 shares at December 31, 2024)	−1,802	—	—	—	−1,804
Additional paid-in capital	1,074	—	—	—	1,055
Retained earnings	1,220	1,282	1,249	1,642	1,685
Accumulated other comprehensive loss	−244	−278	−286	−334	−367
Total Chemours stockholders equity	250	274	228	566	571
Non-controlling interests	1	—	—	—	1
Total equity	251	276	230	567	572
Total liabilities and equity	7,382	7,546	7,462	7,376	7,509

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	340	292	309	291	317
Gain on sales of assets and businesses, net	−8	−3	−110	−21	−115
Equity in earnings of affiliates, net	−7	−1	11	−22	−11
Amortization of debt issuance costs and issue discounts	11	12	9	9	9
Deferred tax provision (benefit)	64	−31	−143	20	−77
Asset-related charges	32	27	95	5	0
Stock-based compensation expense	21	15	18	27	34
Net periodic pension (income) cost	−2	6	9	9	6
Defined benefit plan contributions	−2	−12	−10	−10	−17
Other operating charges and credits, net	18	−42	1	−21	18
Accounts and notes receivable, net	106	−139	−14	91	−225
Inventories and other current operating assets	−106	−140	61	−294	−210
Other non-current operating assets	66	−98	—	−96	8
Accounts payable	−165	4	−74	105	281
Other current operating liabilities	−3	−660	642	−47	97
Non-current operating liabilities	280	11	3	138	70
Cash provided by (used for) operating activities	264	−633	556	755	814
Purchases of property, plant, and equipment	−213	−360	−370	−307	−277
Proceeds from sales of assets and businesses, net of cash divested	7	3	143	33	508
Foreign exchange contract settlements, net	−1	2	−8	3	−12
Other investing activities	1	2	6	−13	1
Cash used for investing activities	−206	−353	−229	−284	220
Proceeds from issuance of debt, net	748	606	648	0	650
Debt repayments	−787	−490	−280	−68	−854
Payments of debt issuance costs	−7	−9	−4	−1	−11
Payments on finance leases	−14	−12	−11	−11	−10
Proceeds from supplier financing programs	80	93	123	105	91
Payments to supplier financing program	−88	−102	−87	−106	−85
Purchases of treasury stock, at cost	—	—	−69	−495	−173
Proceeds from exercised stock options	—	9	19	51	23
Payments related to tax withheld on vested stock awards	−1	−3	−19	−6	−2
Payments of dividends to the Company's common shareholders	−78	−148	−149	−154	−164
(Distributions to) cash received from non-controlling interest shareholders	—	−1	1	−1	−1
Other financing activities	21	21	—	—	—
Cash (used for) provided by financing activities	−126	−36	172	−686	−554
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents	29	−22	4	−32	−34
(Decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents	−39	−1,044	503	−247	446
Interest, net of amounts capitalized	251	267	223	164	180
Income taxes, net of refunds	74	82	63	131	149
Purchases of property, plant, and equipment included in accounts payable	33	88	82	79	89

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro